IDO1 and metastatic neoplasm: In order to evaluate the influence of PD-L1 and IDO expression on response to immunotherapy and survival, protein expression was assessed in 86 pretreatment melanoma biopsies from patients with metastatic disease before initiation of checkpoint inhibitor therapy.